Finance

Lists
Why is CRVS down 3,35%?
Dive Deeper
CRVS:NASDAQ
Corvus Pharmaceuticals Inc
9,52 $
-3,35%
(-0,33) 1D
9,50 $
-0,21% (-0,020)
After hours
Closed: 16 հոկ, 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CRVS...
Open
9,81 $
High
10,12 $
Low
9,43 $
Mkt. cap
800,83 մլն
Avg. vol.
1,23 մլն
Volume
1,04 մլն
52-wk high
26,95 $
52-wk low
6,39 $
EPS
-0,62 $
Beta
1,44
Shares outstanding
84,12 մլն
No. of employees
37
Open
9,81 $
High
10,12 $
Low
9,43 $
Mkt. cap
800,83 մլն
Avg. vol.
1,23 մլն
Volume
1,04 մլն
52-wk high
26,95 $
52-wk low
6,39 $
EPS
-0,62 $
Beta
1,44
Shares outstanding
84,12 մլն
No. of employees
37
News stories
From web sources and news partners
About Corvus Pharmaceuticals Inc
CEO-
Employees37
Founded2014
HeadquartersBurlingame, Կալիֆոռնիա, Միացյալ Նահանգներ
Sector-
Websitecorvuspharma.com
Analyst ratings
Based on 4 analysts giving stock ratings to CRVS in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for CRVS in the last 3 months.
Highest
Current 9,52 $
33,00 $ (+246,64%)
Average
29,50 $ (+209,87%)
Lowest
27,00 $ (+183,61%)
Analyst
Recommendation
Action
Price target
Projected
Date
Graig Suvannavejh
Mizuho Securities
Buy
Reiterated
30,00 $
+215,1%
08/11/2026
Sean Lee CFA
H.C. Wainwright
Buy
Maintained
27,00 $
+183,6%
08/10/2026
Unknown Analyst
Oppenheimer
Buy
Reiterated
33,00 $
+246,6%
08/07/2026
Jeff Jones
Oppenheimer
Buy
Reiterated
33,00 $
+246,6%
08/07/2026
Etzer Darout
Barclays
Buy
Maintained
28,00 $
+194,1%
08/07/2026
Paul Choi
Goldman Sachs
Buy
Maintained
40,00 $
+320,2%
05/14/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
8,45 մլն
9,94 մլն
11,18 մլն
15,96 մլն
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2,12 մլն
2,28 մլն
3,70 մլն
3,33 մլն
Operating expense
10,57 մլն
12,22 մլն
14,88 մլն
19,30 մլն
Total operating expenses
10,57 մլն
12,22 մլն
14,88 մլն
19,30 մլն
Operating income
-10,57 մլն
-12,22 մլն
-14,88 մլն
-19,30 մլն
Other non operating income
-
-
-
-
EBT including unusual items
-10,16 մլն
-12,32 մլն
-13,69 մլն
-17,96 մլն
EBT excluding unusual items
-10,16 մլն
-12,32 մլն
-13,69 մլն
-17,96 մլն
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-10,16 մլն
-12,32 մլն
-13,69 մլն
-17,96 մլն
Net profit margin
-
-
-
-
Earnings per share
-0,12
-0,15
-0,15
-0,19
Interest and investment income
738,00 հզր
603,00 հզր
1,78 մլն
2,05 մլն
Interest expense
-
-
-
-
Net interest expenses
738,00 հզր
603,00 հզր
1,78 մլն
2,05 մլն
Depreciation and amortization charges
-
-
-
-
EBITDA
-10,54 մլն
-12,19 մլն
-14,85 մլն
-19,26 մլն
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google Apps